Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for the Prevention of Migraine in Adults With a History of Inadequate Response to Oral Preventive Medications
NCT05518123Phase 4Completed
- Sponsor
- Pfizer
- Start
- Nov 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 4, randomised, double-blind trial in migraine comparing Rimegepant 75 mg with Placebo (2 arms). Primary endpoint: Mean Change From Observation Phase in the Number of Migraine Days Per Month at 12 weeks. Started Nov 2022; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05518123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518123.